Literature DB >> 27587627

Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer.

Kari E Hacker1, Shitanshu Uppal1, Carolyn Johnston1.   

Abstract

Borderline ovarian tumors (BOTs) are less common than epithelial ovarian cancers (EOCs). Low-grade EOCs (LG-EOCs) occur even less frequently than BOTs. After primary therapy, recurrence rates of BOTs and LG-EOCs are significantly lower and the stage-adjusted survival is higher than for high-grade EOCs. Thus, determining the best management in terms of traditional ovarian cancer staging and debulking procedures is more challenging and has been recently brought to question. This article reviews the particulars of BOTs and LG-EOCs, their similarities and differences, and how they are best managed and treated, and emphasizes the major role of surgery and the controversial role of chemotherapy. Because these tumors disproportionately affect younger women, this review addresses ovarian preservation in circumstances when fertility or hormonal preservation is desired.
Copyright © 2016 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2016        PMID: 27587627     DOI: 10.6004/jnccn.2016.0124

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  4 in total

1.  The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.

Authors:  Yan Zhang; Qian Mei; Yang Liu; Xiang Li; Malcolm V Brock; Meixia Chen; Liang Dong; Lu Shi; Yao Wang; Mingzhou Guo; Jing Nie; Weidong Han
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

2.  Digital Pathology-based Study of Cell- and Tissue-level Morphologic Features in Serous Borderline Ovarian Tumor and High-grade Serous Ovarian Cancer.

Authors:  Jun Jiang; Burak Tekin; Ruifeng Guo; Hongfang Liu; Yajue Huang; Chen Wang
Journal:  J Pathol Inform       Date:  2021-06-05

3.  Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Authors:  Tian Zhang; Jing Wang; Yanjun Su; Xi Chen; Qingna Yan; Qi Li; Leina Sun; Yuwen Wang; Puchun Er; Qingsong Pang; Ping Wang
Journal:  Oncotarget       Date:  2017-06-20

4.  Systematic Lymph Node Dissection May Be Abolished in Patients With Apparent Early-Stage Low-Grade Mucinous and Endometrioid Epithelial Ovarian Cancer.

Authors:  Jiayu Chen; Jie Yin; Yan Li; Yu Gu; Wei Wang; Ying Shan; Yong-Xue Wang; Meng Qin; Yan Cai; Ying Jin; Lingya Pan
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.